Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates - Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase 1b trial initiation expected in Q4 2025 - - CPVT (SGT-501): Phase 1b trial initiation expected in Q4 2025 - - Capsids (AAV-SLB101): Over 25 agreements or licenses with academic labs, institutions and corporations for the use of AAV-SLB101 have been executed - - Cash: Company ended Q2 2025 with $26...
Two Directors at Harley-Davidson Inc bought 3,317 shares at between 0.000USD and 24.060USD. The significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its second quarter financial results and a letter to shareholders from CEO, Jeffrey Kip on the investor relations section of its website at ir.angi.com/quarterly-earnings. As announced previously, Angi Inc. will host a conference call to discuss the company’s second quarter results and to answer questions. The call will be held on Wednesday, August 6, 2025, at 8:30 a.m. ET. Jeffrey Kip, CEO and Andrew Russakoff, CFO will participate...
Frequency Electronics Announces 2025 Quantum Sensing Summit in New York City Event to Accelerate Production-Ready Quantum Sensing Technologies MITCHEL FIELD, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, today announced it will host the 2025 Quantum Sensing Summit on October 29–30, 2025, in New York City. The event will bring together leaders from government, industry, and research to accelerate the transition of quantum sensing technologies from the lab t...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted stock units (“RSUs”) to four newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s ...
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - CHARLESTOWN, Mass., July 23, 2025 (GLOBE NEWSW...
Angi Inc. to Announce Q2 2025 Earnings on August 5th and Host Earnings Conference Call on August 6th DENVER, July 16, 2025 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, August 5, 2025, Angi Inc. (NASDAQ: ANGI) will post its second quarter results and simultaneously CEO Jeff Kip will publish a letter to shareholders, which may include certain forward-looking information, at ir.angi.com/quarterly-earnings. On Wednesday, August 6, 2025, at 8:30 a.m. ET, Angi Inc. will host a conference call to answer questions regarding the company’s second quarter results. The live audi...
Frequency Electronics Issues a Clarification to Yesterday’s Earnings Call MITCHEL FIELD, N.Y., July 11, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency technology, would like to clarify a topic on yesterday’s earnings call. The Company discussed expected near-term revenue from its TURbO compact rubidium atomic clock. As a clarification, although the stated revenue expectation in FY2026 of $1M to $2M is accurate, that comment referred to orders already received since TURbO’s introduction a few...
Frequency Electronics, Inc. Announces Fourth Quarter and Full Fiscal Year 2025 Financial Results MITCHEL FIELD, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is reporting revenues for the three and twelve months ended April 30, 2025, of approximately $20.0 million and $69.8 million, respectively, compared to revenues of $15.6 million and $55.3 million, for the same period of fiscal year 2024, ended April 30, 2024. Operating income for the three and twelve months ended was $3.3 million and $11.7 million, respectively, compared to...
Frequency Electronics Announces Year End Fiscal 2025 Financial Results Conference Call: Thursday, July 10, 2025, at 4:30 PM ET MITCHEL FIELD, N.Y., July 09, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for its fiscal year 2025, ended April 30, 2025, on Thursday, July 10, 2025, at 4:30 PM Eastern Time. This call is being webcast by Issuer Direct Corporation and can be accessed in the Investor Relations section of Frequency’s web site at . Investors and analysts may also access the call by dialing 888-506-0062. Inte...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.